Mirvat Alasnag
PCRonline Editorial Board Advisor
Declaration of interest
| Function | Company |
|---|---|
| None |
Latest contributions
From atherectomy to lithotripsy: choosing the right tool for the right calcium
22 May 2026 – From EuroPCR 2026
Delve into the latest advancements in calcium modification devices and techniques in this session, which guides clinicians through selecting the most appropriate tool based on calcium morphology. Through step-by-step, case-based decision-making, it enhances procedural planning and lesion preparation to optimize interventional outcomes.
TAVI - Procedural strategy
21 May 2026 – From EuroPCR 2026
This session focuses on procedural strategies for TAVI, examining the influence of coronary artery disease severity on PCI decision-making, revascularisation approaches in high-bleeding risk patients, the role of CT imaging and implant depth in procedural planning, and comparative evaluation of pre-dilatation versus direct valve implantation in...
Safe management of assisted PCI : what can go wrong
20 May 2026 – From EuroPCR 2026
Explore the complexities and potential complications associated with assisted PCI in this session. Topics include challenges such as microaxial pump kinks, technical aspects of IMPELLA device deployment, and the management of high-risk PCI cases including patients with prior TAVI, highlighting strategies to mitigate risks during protected...
Rethinking coronary artery disease: from ischaemia to atheroma - Implications of the Lancet Commission for Interventional Cardiology
20 May 2026 – From EuroPCR 2026
This session invites a re-evaluation of coronary artery disease by shifting focus from ischemia to atheroma, integrating insights from the Lancet Commission for Interventional Cardiology. It explores the significance of plaque burden, biology, and inflammation in guiding PCI decisions and outlines the future role of PCI...
Evidence for new devices in management of coronary artery disease
19 May 2026 – From EuroPCR 2026
This session reviews the latest evidence on new devices in coronary artery disease management. It covers outcomes from randomized controlled trials including imaging- and physiology-guided PCI with the Bioadaptor device, long-term results of thinner-strut bioresorbable scaffolds, site-specific antithrombotic therapy evaluated in the DESyne BDS Plus Trial,...
ALL-RISE: A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide PCI
28 Mar 2026
Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.
Author
PCRonline @ ACC 2026 Scientific Sessions
12 Mar 2026
Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2026 Scientific Sessions #ACC26
TAVI - Haemodynamic performance and valve durability
18 Nov 2025 – From PCR London Valves 2025
This session provides an in-depth exploration of haemodynamic performance and valve durability following transcatheter aortic valve implantation (TAVI). Attendees will gain a comprehensive understanding of the differences between invasive and echocardiographic gradients post-TAVI, evaluate the haemodynamic profiles of various transcatheter valve platforms, and appreciate their implications...
Heart Team management of complex valve disease
17 Nov 2025 – From PCR London Valves 2025
Explore the dynamics of managing complex valve disease within a multidisciplinary Heart Team framework. This session discusses strategies for building and sustaining high-functioning teams, integrating multimodality imaging, clinical risk assessment, AI tools, and patient preferences into decision-making, alongside effective communication methods to support collaborative care.
A randomised, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial
27 Oct 2025
Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.
Author
Long-term follow-up of the PARTNER 3 Low-Risk randomised trial: seven-year clinical and echocardiographic outcomes
27 Oct 2025
Mirvat Alasnag interviews Michael J. Mack on the PARTNER 3 Low-Risk randomised trial he presented at TCT 2025 in San Francisco.
Author
Author
PCR @ TCT 2025 - Get the international perspective!
15 Oct 2025
Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2025 - check out the list below.
CLEAR-IE: outcomes of percutaneous mechanical aspiration in right-sided infective endocarditis
06 Oct 2025
Can mechanical aspiration offer a safer, less invasive option for managing right-sided infective endocarditis? The CLEAR-IE registry provides valuable early insights.
Reviewer
Most impactful trials in structural heart disease 2024/2025
30 Sep 2025 – From PCR Gulf Valves 2025
Delve into the most impactful structural heart disease trials shaping 2024 and 2025. This session addresses current dilemmas in TAVI, including early intervention and management of small annuli, evaluates evidence for transcatheter mitral and tricuspid valve repair, and identifies evidence gaps relevant to the region, providing...
Step-by-step TAVI for mixed bicuspid aortic valve disease - LIVE Case
30 Sep 2025 – From PCR Gulf Valves 2025
A 65-year-old female with a history of diabetes and moderate left ventricular dysfunction (LVEF 50%) presented with symptomatic severe bicuspid aortic stenosis associated with moderate-to-severe aortic regurgitation. A 26 mm Sapien Resilia valve was implanted under local anesthesia via femoral artery access, with right radial secondary...
Complex femoral access for TAVI in bicuspid aortic stenosis - LIVE Case
30 Sep 2025 – From PCR Gulf Valves 2025
A 74-year-old male with a history of multiple PCIs, peripheral arterial disease, and type 2 DM presented with symptomatic bicuspid aortic stenosis and preserved LV function.
A 26 mm Myval valve was implanted via right femoral artery access, with right radial secondary access, following predilatation with a...
Tricuspid transcatheter therapies: the game changer
29 Sep 2025 – From PCR Gulf Valves 2025
Explore the evolving landscape of tricuspid transcatheter therapies in this comprehensive session reviewing tricuspid regurgitation etiology, anatomy, and current treatment options. Learn about various transcatheter tricuspid valve intervention devices, their strengths and limitations, and the critical diagnostic and intraprocedural imaging requirements to optimize patient selection and...
Redefining standards: TAVI in the era of lifetime management, beyond high-risk patients
29 Sep 2025 – From PCR Gulf Valves 2025
Discover a selection of cases showcasing the key features of the Navitor Valve System and its clinical applications. This session explores auxiliary access, the use of Navitor in alternative access and complex PCI, its performance in challenging peripheral anatomies, and innovative outcomes with the Vantage 30D...
Myval transcatheter heart valve series - Align for the future with novel design, data and daily clinical experience
29 Sep 2025 – From PCR Gulf Valves 2025
Join this comprehensive session to explore the Myval transcatheter heart valve series, featuring the latest clinical updates from two large randomized controlled trials—Landmark and Compare TAVI. Learn from real-world experiences, including recorded cases, and understand how these innovations translate to complex patient demographics in daily TAVI...
OPTION-STEMI: Immediate versus staged complete revascularisation during index admission in patients with STEMI and multivessel disease
02 Sep 2025
Mirvat Alasnag provides her take on OPTION-STEMI, presented by Youngkeun Ahn at ESC Congress 2025 in Madrid.
Author
PCRonline @ ESC Congress 2025: the interventional cardiology perspective!
26 Jul 2025
Stay updated with the latest in interventional cardiology at #ESCCongress 2025!
PCI for complex bifurcation disease - LIVE Case
23 May 2025 – From EuroPCR 2025
A 60-year-old male patient presented with an inferior STEMI one month ago, which was treated with RCA and LCx PCI. He was referred for LAD/diagonal PCI. The LV function was reduced (EF 45 %). The team performed a DK crush PCI, guided by IVUS.
LIVE Educational Case...
Advancing the standard of care in PCI with Bioadaptor: from simple to complex
21 May 2025 – From EuroPCR 2025
This session provides an in-depth overview of Bioadapter technology and its potential to overcome the limitations of current drug-eluting stents (DES) in percutaneous coronary intervention (PCI). Speakers present data from recent trials, including the Bioadapter RCT and the Infinity Sweetheart study, demonstrating a reduction in target lesion...
Through decisions in complex left main PCI - Isolated ostial left circumflex
21 May 2025 – From EuroPCR 2025
Navigate complex isolated ostial left circumflex lesions with a focus on the integration of imaging and physiological assessment. Learn treatment options and optimisation strategies to improve long-term outcomes in left main PCI through detailed case presentations and expert guidance.
Cardiogenic shock and high-risk interventions with percutaneous mechanical circulatory support: new evidence and insights
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session offers a comprehensive update on cardiogenic shock and high-risk PCI, featuring expert analysis of the DanGer-SHOCK and ECLS-SHOCK trials, new insights one year after DanGer-SHOCK, and practical considerations for managing PCI in patients with severely reduced LVEF. Expect to gain a deeper...
The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma
01 Apr 2025
Mirvat Alasnag provides her take on the Lancet Commission for atherosclerosis published during the ACC.25 in Chicago.
Author
Early intra-aortic balloon pump in heart failure complicated by cardiogenic shock: The Altshock-2 randomized clinical trial
31 Mar 2025
Mirvat Alasnag provides her take on the Altshock-2 randomized clinical trial which was presented by Alice Sacco at ACC.25 in Chicago.
Author
PCRonline @ ACC.25 Scientific Sessions
07 Feb 2025
Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2025 Scientific Sessions #ACC25
Mechanical circulatory support: role in the management of high-risk PCI and AMI-cardiogenic shock
19 Dec 2024 – From GulfPCR-GIM 2024
This session highlights the essential role of mechanical circulatory support (MCS) in managing high-risk PCI and AMI-related cardiogenic shock. Explore case-based discussions on device selection, hemodynamic impact, and evidence-based strategies to optimize outcomes in complex scenarios.
Align for the future with Myval THV series and complex PCI solutions
18 Dec 2024 – From GulfPCR-GIM 2024
Explore the future of complex PCI with Meril Life’s advanced solutions. Learn about thin-strut platforms, dedicated stents for side branches and diffuse lesions, the role of drug-eluting balloons in metal-free PCI, and the clinical potential of the Myval THV technology.
